Theraclone Sciences Inc. was to present data Sept. 8 showing TCN-032 missed the primary endpoint in a Phase IIa influenza viral challenge study. However, the company says the endpoint, rather than the mAb, was the problem.

Based on a trend of symptomatic improvement and significant improvements on secondary endpoints including viral shedding and clinical measures, Theraclone hopes to get a government contract to fund the rest of the Phase II program, with an initial focus on seriously ill hospitalized flu patients.